is the much-anticipated new hepatitis B drug that within weeks
hepatitis B virus, enabling patients to lose the hepatitis B
antigen—something no other drug has been able to do. In this
when interferon was added to REP 9AC, patients even developed
antibodies—essentially permanently getting rid of the infection.
—Christine. M. Kukka, Project Manager, HBV Advocate
"Short Term Immunotherapy Following REP 9AC..." by Al-Mahtab,
and Vaillant. Asian Pacific Association for the Study of Liver
& 15th annual TIDES meeting.
Labels: drugs in development, REP 9AC, treatment